88
Participants
Start Date
August 31, 2014
Primary Completion Date
February 29, 2016
Study Completion Date
February 29, 2016
VRC01
Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
SC placebo for VRC01
Sterile, buffered aqueous solution of 25 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM L-Arginine Hydrochloride, 10% Dextran 40, and 0.005% Polysorbate 80 at pH 5.8 administered SC by needle and syringe injection
IV placebo for VRC01
Sodium Chloride for Injection 0.9%, USP administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP)
New York Blood Center CRS, New York
Penn Prevention CRS, Philadelphia
Case Clinical Research Site, Cleveland
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston
Fenway Health (FH) CRS, Boston
Columbia P&S CRS, New York
National Institute of Allergy and Infectious Diseases (NIAID)
NIH